Pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine at steady state in healthy volunteers

Epilepsia

Volumn 54, Issue 8, 2013, Pages 1453-1461

  Elger, Christian ^a   Bialer, Meir ^b   Falcão, Amílcar ^c   Vaz Da Silva, Manuel ^d,e   Nunes, Teresa ^d   Almeida, Luís ^f   Soares Da Silva, Patrício ^d,e  

^a UNIVERSITY OF BONN   (Germany)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c UNIVERSITY OF COIMBRA   (Portugal)

^d DEPARTMENT OF RESEARCH AND DEVELOPMENT   (Portugal)

^e University of Porto   (Portugal)

^f UNIVERSITY OF AVEIRO   (Portugal)

Author keywords

Eslicarbazepine acetate; Healthy volunteers; Once daily; Oxcarbazepine; Pharmacokinetics; Tolerability; Twice daily

Indexed keywords

ESLICARBAZEPINE; ESLICARBAZEPINE ACETATE; LICARBAZEPINE; OXCARBAZEPINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN EXPERIMENT; MACULAR RASH; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; REPEATED DRUG DOSE; SIDE EFFECT; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION; UNSPECIFIED SIDE EFFECT;

ESLICARBAZEPINE ACETATE; HEALTHY VOLUNTEERS; ONCE-DAILY; OXCARBAZEPINE; PHARMACOKINETICS; TOLERABILITY; TWICE-DAILY;

ADULT; ANTICONVULSANTS; AREA UNDER CURVE; CARBAMAZEPINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; DIBENZAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCARDIOGRAPHY; ELECTROCHEMISTRY; FEMALE; HEART RATE; HUMANS; MALE; TIME FACTORS;

EID: 84881177072     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/epi.12242     Document Type: Article

References (36)

1. Aires C, Hebeisen S, Soares-da-Silva P,. (2012) Effects of eslicarbazepine, R-licarbazepine and oxcarbazepine on fast and slow inactivation of voltage-gated sodium channels. Epilepsia 53 (Suppl. 5): 51.
2. Almeida L, Soares-da-Silva P,. (2004) Safety, tolerability, and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic, in a rising multiple-dose study in young healthy humans. J Clin Pharmacol 44: 906-918.
3. Almeida L, Soares-da-Silva P,. (2007) Eslicarbazepine acetate (BIA 2-093). Neurotherapeutics 4: 88-96.
4. Almeida L, Falcao A, Maia J, Mazur D, Gellert M, Soares-da-Silva P,. (2005) Single-dose and steady-state pharmacokinetics of eslicarbazepine acetate (BIA 2-093) in healthy elderly and young subjects. J Clin Pharmacol 45: 1062-1066.
5. Almeida L, Minciu I, Nunes T, Butoianu N, Falcao A, Magureanu SA, Soares-da-Silva P,. (2008a) Pharmacokinetics, efficacy, and tolerability of eslicarbazepine acetate in children and adolescents with epilepsy. J Clin Pharmacol 48: 966-977.
6. Almeida L, Potgieter JH, Maia J, Potgieter MA, Mota F, Soares-da-Silva P,. (2008b) Pharmacokinetics of eslicarbazepine acetate in patients with moderate hepatic impairment. Eur J Clin Pharmacol 64: 267-273.
7. Almeida L, Bialer M, Soares-da-Silva P,. (2009) Eslicarbazepine acetate. In, Shorvon S, Perucca E, Engel J, (Eds) The treatment of epilepsy. Blackwell Publishing, Oxford, pp. 485-498.
8. Ambrosio AF, Silva AP, Araujo I, Malva JO, Soares-da-Silva P, Carvalho AP, Carvalho CM,. (2000) Neurotoxic/neuroprotective profile of carbamazepine, oxcarbazepine and two new putative antiepileptic drugs, BIA 2-093 and BIA 2-024. Eur J Pharmacol 406: 191-201.
9. Ambrosio AF, Soares-da-Silva P, Carvalho CM, Carvalho AP,. (2002) Mechanisms of action of carbamazepine and its derivatives, oxcarbazepine, BIA 2-093, and BIA 2-024. Neurochem Res 27: 121-130.
10. Araujo IM, Ambrosio AF, Leal EC, Verdasca MJ, Malva JO, Soares-da-Silva P, Carvalho AP, Carvalho CM,. (2004) Neurotoxicity induced by antiepileptic drugs in cultured hippocampal neurons: a comparative study between carbamazepine, oxcarbazepine, and two new putative antiepileptic drugs, BIA 2-024 and BIA 2-093. Epilepsia 45: 1498-1505.
11. Benes J, Parada A, Figueiredo AA, Alves PC, Freitas AP, Learmonth DA, Cunha RA, Garrett J, Soares-da-Silva P,. (1999) Anticonvulsant and sodium channel-blocking properties of novel 10,11- dihydro-5H-dibenz[b, f]azepine-5-carboxamide derivatives. J Med Chem 42: 2582-2587.
12. Ben-Menachem E, Gabbai AA, Hufnagel A, Maia J, Almeida L, Soares-da-Silva P,. (2010) Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy. Epilepsy Res 89: 278-285.
13. Bialer M, Soares-da-Silva P,. (2012) Pharmacokinetics and drug interactions of eslicarbazepine acetate. Epilepsia 53: 935-946.
14. Bonifacio MJ, Sheridan RD, Parada A, Cunha RA, Patmore L, Soares-da-Silva P,. (2001) Interaction of the novel anticonvulsant, BIA 2-093, with voltage-gated sodium channels: comparison with carbamazepine. Epilepsia 42: 600-608.
15. v3.2 channels. Epilepsia 52 (Suppl. 6): 260.
16. Bulling A, Hebeisen S, Konrad D, Soares-da-Silva P,. (2011) Effects of eslicarbazepine, R-licarbazepine and carbamazepine on NMDA and AMPA receptor-mediated currents. Epilepsia 52 (Suppl. 6): 258.
17. Elger C, Bialer M, Cramer JA, Maia J, Almeida L, Soares-da-Silva P,. (2007) Eslicarbazepine acetate: a double-blind, add-on, placebo-controlled exploratory trial in adult patients with partial-onset seizures. Epilepsia 48: 497-504.
18. Elger C, Halasz P, Maia J, Almeida L, Soares-da-Silva P,. (2009) Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study. Epilepsia 50: 454-463.
19. Falcao A, Maia J, Almeida L, Mazur D, Gellert M, Soares-Da-Silva P,. (2007) Effect of gender on the pharmacokinetics of eslicarbazepine acetate (BIA 2-093), a new voltage-gated sodium channel blocker. Biopharm Drug Dispos 28: 249-256.
20. Faught E, Limdi N,. (2009) Oxcarbazepine. In, Shorvon S, Perucca E, Engel J, (Eds) The treatment of epilepsy. Blackwell Publishing, Oxford, pp. 575-584.
21. Gil-Nagel A, Lopes-Lima J, Almeida L, Maia J, Soares-Da-Silva P,. (2009) Efficacy and safety of 800 and 1200 mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures. Acta Neurol Scand 120: 281-287.
22. Gil-Nagel A, Elger C, Ben-Menachem E, Halasz P, Lopes-Lima J, Gabbai AA, Nunes T, Falcao A, Almeida L, Soares-da-Silva P,. (2013) Efficacy and safety of eslicarbazepine acetate as add-on treatment in patients with focal-onset seizures: integrated analysis of pooled data from double-blind phase III clinical studies. Epilepsia 54: 98-107.
23. Hainzl D, Parada A, Soares-da-Silva P,. (2001) Metabolism of two new antiepileptic drugs and their principal metabolites S(+)- and R(-)-10,11-dihydro-10-hydroxy carbamazepine. Epilepsy Res 44: 197-206.
24. Halasz P, Cramer JA, Hodoba D, Czlonkowska A, Guekht A, Maia J, Elger C, Almeida L, Soares-da-Silva P,. (2010) Long-term efficacy and safety of eslicarbazepine acetate: results of a 1-year open-label extension study in partial-onset seizures in adults with epilepsy. Epilepsia 51: 1963-1969.
25. Hebeisen S, Brady K, Konrad D, Soares-da-Silva P,. (2011) Inhibitory effects of eslicarbazepine acetate and its metabolites against neuronal voltage-gated sodium channels. Epilepsia 52 (Suppl. 6): 257-258.
26. v1.8 channels. Epilepsia 53 (Suppl. 5): 47-48.
27. Hufnagel A, Ben-Menachem E, Gabbai AA, Falcao A, Almeida L, Soares-da-Silva P,. (2013) Long-term safety and efficacy of eslicarbazepine acetate as adjunctive therapy in the treatment of partial-onset seizures in adults with epilepsy: results of a 1-year open-label extension study. Epilepsy Res 103: 262-269.
28. Maia J, Almeida L, Falcão A, Soares E, Mota F, Potgieter JH, Potgieter MA, Soares-da-Silva P,. (2008) Effect of renal impairment on the pharmacokinetics of eslicarbazepine acetate. Int J Clin Pharmacol Ther 46: 119-130.
29. Nunes T, Rocha JF, Falcao A, Almeida L, Soares-da-Silva P,. (2013) Steady-state plasma and cerebrospinal fluid pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine in healthy volunteers. Epilepsia 54: 108-116.
30. Pekcec A, Potschka H, Soares-da-Silva P,. (2011) Effects of eslicarbazepine acetate and its metabolites in the corneal kindling model of epilepsy. Epilepsia 52 (Suppl. 6): 257.
31. Perucca E, Elger C, Halasz P, Falcao A, Almeida L, Soares-da-Silva P,. (2011) Pharmacokinetics of eslicarbazepine acetate at steady-state in adults with partial-onset seizures. Epilepsy Res 96: 132-139.
32. Pires N, Palma N, Loureiro AI, Bonifacio MJ, Wright LC, Soares-da-Silva P,. (2011) Effects of eslicarbazepine acetate, eslicarbazepine, carbamazepine and oxcarbazepine in the maximal electroconvulsive shock test in the mice. Epilepsia 52 (Suppl. 6): 118.
33. Soares-da-Silva P, Hebeisen S,. (2012) Slow and fast inactivation of voltage-gated sodium channels by eslicarbazepine and carbamazepine. Epilepsia 53 (Suppl. 5): 54.
34. v7.2 channels. Epilepsia 52 (Suppl. 6): 258-259.
35. Torrao L, Machado R, Pires N, Palma N, Bonifacio MJ, Wright LC, Soares-da-Silva P,. (2011) Effects of eslicarbazepine acetate, eslicarbazepine, carbamazepine and oxcarbazepine in the 6-HZ psychomotor seizure model in the mice. Epilepsia 52 (Suppl. 6): 118-119.
36. Volosov A, Xiaodong S, Perucca E, Yagen B, Sintov A, Bialer M,. (1999) Enantioselective pharmacokinetics of 10-hydroxycarbazepine after oral administration of oxcarbazepine to healthy Chinese subjects. Clin Pharmacol Ther 66: 547-553.